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ABSTRACT
Objective To evaluate the association between door-to-
balloon time and mortality in hospital in patients
undergoing primary percutaneous coronary intervention
for ST elevation myocardial infarction to assess the
incremental mortality benefit of reductions in door-to-
balloon times of less than 90 minutes.
Design Prospective cohort study of patients enrolled in
the American College of Cardiology National
Cardiovascular Data Registry, 2005-6.
Setting Acute care hospitals.
Participants43801patientswithSTelevationmyocardial
infarction undergoing primary percutaneous coronary
intervention.
Main outcome measure Mortality in hospital.
Results Median door-to-balloon time was 83 minutes
(interquartile range 6-109, 57.9% treated within
90 minutes). Overall mortality in hospital was 4.6%.
Multivariable logistic regression models with fractional
polynomial models indicated that longer door-to-balloon
times were associated with a higher adjusted risk of
mortality in hospital in a continuous non-linear fashion
(30minutes=3.0%,60minutes=3.5%,90minutes=4.3%,
120 minutes=5.6%, 150 minutes=7.0%, 180 minutes
=8.4%,P<0.001).Areductionindoor-to-balloontimefrom
90 minutes to 60 minutes was associated with 0.8%
lower mortality, and a reduction from 60 minutes to
30 minutes with a 0.5% lower mortality.
Conclusion Any delay in primary percutaneous coronary
intervention after a patient arrives at hospital is
associated with higher mortality in hospital in those
admitted with ST elevation myocardial infarction. Time to
treatment should be as short as possible, even in centres
currently providing primary percutaneous coronary
intervention within 90 minutes.
INTRODUCTION
Clinical guidelines recommend that hospitals provid-
ing primary percutaneous coronary intervention to
patients with ST segment elevation myocardial infarc-
tion should treat patients within 90 minutes of contact
with the medical system or admission to hospital.
1
Although most studies point to an independent asso-
ciation between longer time to treatment and higher
mortality, the specific shape of the relation between
mortality risk and time to treatment is unclear. While
some studies indicate that any delay after admission is
associated with higher mortality,
2-11 others suggest
mortality is higher only after an initial delay in treat-
ment of an hour or more.
1213 In addition, it is unclear
whether mortality is higher with successively longer
times to treatment,
2-69101213 or if mortality eventually
plateaus after two or more hours of delay.
7111415
Clarifying the specific shape of the association
between door-to-balloon time (that is, between arrival
at hospital and treatment) and mortality is important
given recent efforts to reduce delays. Current quality
improvement initiatives, such as the Door-to-Balloon
Alliance, seek to achieve a door-to-balloon time of
90minutesorlessamong75%ormoreofpatientsunder-
going primary percutaneous coronary intervention at
participating hospitals.
16 Several hospitals have shown
that it is possible to push beyond this benchmark and
achieve median door-to-balloon times approaching
60 minutes.
17 Relatively little data exist regarding the
incremental benefit of further reductions beyond
90 minutes.
We analysed data from the American College of
Cardiology National Cardiovascular Data Registry, a
large national database containing detailed medical
records of community patients undergoing percuta-
neous coronary intervention. We hypothesised that
any increase in door-to-balloon time would be asso-
ciated with increased mortality and that this mortality
risk would persist irrespective of the length of the delay
in treatment.
METHODS
National Cardiovascular Data Registry
The registry, described in detail elsewhere, is spon-
sored by the American College of Cardiology and
contains details of patients undergoing cardiac
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intheUnitedStates.Siteswereencouragedtoprospec-
tively collect detailed clinical information including
medical history, indications for procedure, angio-
graphic findings, treatment, events, and procedural
outcomes, from all patients undergoing cardiac cathe-
terisation. Data quality was ensured through the use of
standardised data elements and definitions, systematic
data entry with common registry software, an onsite
audit programme, and transmission to a central data
warehouse for additional review before analysis.
Study sample
Welimitedouranalysistopatientswho,in2005-6,pre-
sented to a participating centre within 12 hours of
symptom onset with laboratory and electrocardio-
graphic evidence of ST elevation myocardial infarc-
tion and subsequently underwent primary
percutaneous coronary intervention (n=64676). We
excluded patients who were transferred from other
hospitals (n=17992) because we could not evaluate
their status on admission. We also excluded patients
who first received fibrinolytic therapy and were subse-
quently referred for primary percutaneous coronary
intervention (n=3313). Patients under 18 years or over
99years(n=9)wereexcludedtofocusanalysisonadult
Table 1 |Distribution of door-to-balloon time in patients
undergoing primary percutaneous coronary intervention for
ST elevation myocardial infarction
Time (minutes) Proportion of cohort (No)
≤30 3.2 (1396)
31-60 19.6 (8575)
61-90 35.1 (15 388)
91-120 23.3 (10 208)
121-150 9.8 (4283)
151-180 4.2 (1856)
181-210 2.0 (895)
211-240 1.1 (469)
≥241 1.7 (731)
Table 2 |Patients’ characteristics and door-to-balloon time in patients undergoing primary percutaneous coronary
intervention for ST elevation myocardial infarction. Figures are percentages of patients unless stated otherwise
Characteristic Overall
Door-to-balloon time (minutes)
Overall P P for trend <60 60-89 90-119 ≥120
No of patients 43 801 9971 15 388 10 208 8234 ——
Demographics:
Median age (IQR) 59 (51-70) 58 (51-68) 59 (51-69) 60 (51-71) 61 (52-73) <0.001 <0.001
Women 27.9 24.8 25.8 29.2 34.0 <0.001 <0.001
White race 84.7 86.3 85.5 84.2 81.8 <0.001 <0.001
Medical history:
Previousmyocardialinfarction 18.3 16.5 17.4 19.4 21.1 <0.001 <0.001
Previous heart failure 4.1 3.0 3.3 4.5 6.6 <0.001 <0.001
Diabetes 20.0 17.5 18.4 21.1 24.9 <0.001 <0.001
Renal failure 2.4 1.6 2.0 2.6 4.0 <0.001 <0.001
Hypertension 59.0 55.2 57.1 60.3 65.4 <0.001 <0.001
Cerebrovascular disease 6.5 5.5 5.7 7.0 8.5 <0.001 <0.001
Peripheral vascular disease 6.2 5.2 5.4 6.3 8.8 <0.001 <0.001
Current tobacco use 44.1 46.2 45.4 43.8 39.4 <0.001 <0.001
Chronic lung disease 11.5 10.7 10.8 11.8 13.5 <0.001 <0.001
Dyslipidaemia 57.3 57.4 56.8 57.4 57.9 0.083 0.38
Family history of early onset
CAD
23.3 24.1 22.9 23.2 23.0 0.28 0.16
Previous PCI 19.3 18.4 18.3 20.2 20.9 <0.001 <0.001
Previous CABG 5.7 3.2 4.4 6.9 9.7 <0.001 <0.001
Admission findings:
Admitted <6 hours after
symptom onset
90.9 92.4 92.6 90.8 86.4 <0.001 <0.001
Heart failure on admission 8.4 6.8 7.2 8.7 12.1 <0.001 <0.001
Cardiogenic shock 9.5 8.6 8.9 9.6 11.7 <0.001 <0.001
NYHA class:
I 24.2 26.3 23.5 23.4 23.8
<0.001 —
II 5.8 5.6 5.2 6.2 6.8
III 15.7 14.7 15.5 16.2 16.7
IV 54.3 53.4 55.9 54.2 52.6
IQR=interquartile range, CAD=coronary artery disease, PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft, NYHA=New York
Heart Association.
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intervention. Finally, to minimise data coding errors,
we excluded patients treated at hospitals that reported
fewer than five primary percutaneous coronary inter-
ventions (n=29). A total of 18989 patients met one or
more of the above exclusion criteria, leaving 45687
patients eligible for analysis.
Door-to-balloon time
Door-to-balloon time was defined as the time in min-
utes between a patient’s arrival at the hospital and the
first balloon inflation or device deployment as docu-
mented in the patient’s medical record. For the pur-
pose of evaluating differences in patients’
characteristics associated with time to treatment we
divided patients into four groups: <60, 60-89, 90-119,
and ≥120 minutes.For all other analyses, we modelled
door-to-balloon time as a continuous variable.
Of the 45687 patients eligible for analysis, we
excluded 503 for whom door-to-balloon time was
missing. Patients with a door-to-balloon time
<15 minutes (n=971) were excluded to avoid poten-
tially incorrectly coded times. Patients with a door-to-
balloon time >6 hours (n=915) were also excluded
becausetheypresumablydidnotreceivepercutaneous
coronary intervention as a primary reperfusion
strategy. The final study sample therefore consisted of
43801 patients.
Statistical analysis
We first determined the mean, median, and distribu-
tion of door-to-balloon times. Differences in patients’
demographic and clinical characteristics were com-
pared across the four door-to-balloon time groups
withχ
2testsandtrendanalysesforcategoricalvariables
and analyses of variance for continuous variables.
Weconductedlogisticregressionanalysisusingfrac-
tional polynomial modelling to determine the specific
shape of the unadjusted association between door-to-
balloontimeandmortalityinhospital.Fractionalpoly-
nomial modelling compares models of different com-
binations of linear and non-linear transformations of
door-to-balloon time to identify those models that
best reflect the association of time to treatment and
mortality. We identified best fitting transformations
by comparison of model deviances using a χ
2distribu-
tion with 1 degree of freedom.
We repeated analyses adjusting for patients’ charac-
teristicsassociatedwithmortalityderivedfromthereg-
istry mortality model.
18 Variables included sex, race,
age, findings at presentation (shock, renal failure, time
from symptom onset to admission), medical history
(diabetes, left ventricular ejection fraction, chronic
Table 3 |Procedural characteristics and door-to-balloon time in patients undergoing primary percutaneous coronary
intervention for ST elevation myocardial infarction. Figures are percentages of patients unless stated otherwise
Overall
Door-to-balloon time (minutes)
Overall P P for trend <60 60-89 90-119 ≥120
No of patients 43 801 9971 15 388 10 208 8234 ——
Weekend procedure 28.2 17.0 28.2 34.7 33.7 <0.001 <0.001
Time of presentation:
Weekday 0000-0759 17.0 11.2 16.7 20.5 20.2
<0.001 —
Weekday 0800-1559 32.8 52.8 31.9 21.9 23.6
Weekday 1600-2359 22.0 19.0 23.2 22.9 22.6
Weekend 0000-0759 6.6 3.1 6.0 9.4 8.7
Weekend 0800-1559 12.5 8.6 12.6 14.5 14.4
Weekend 1600-2359 9.0 5.3 9.5 10.8 10.5
Angiographic findings
Mean (SD) No of lesions 1.3 (0.6) 1.3 (0.6) 1.3 (0.6) 1.3 (0.6) 1.4 (0.7) 0.035 0.022
Stenosis locations:
Left main 2.7 2.2 2.7 2.8 3.4 <0.001 <0.001
Left anterior descending 55.0 51.4 54.0 56.2 59.6 <0.001 <0.001
Circumflex 33.3 29.8 31.8 34.6 38.4 <0.001 <0.001
Right coronary artery 59.8 60.7 60.5 59.9 57.4 <0.001 <0.001
IABP used 10.8 10.0 10.4 11.0 12.4 <0.001 <0.001
Thrombin inhibitors 10.8 11.3 10.7 9.9 11.4 0.003 0.61
Non-stent device used 90.6 91.8 91.4 90.2 88.1 <0.001 <0.001
SCAI classification:
Not reported 0.5 0.4 0.5 0.6 0.7
<0.001 —
I 16.5 14.1 15.6 17.6 19.6
II 19.6 17.2 18.9 21.1 22.1
III 21.2 23.3 21.8 20.0 18.8
IV 42.2 45.0 43.2 40.6 38.7
IABP=intra-aortic balloon pump, SCAI=Society for Cardiac Angiography and Interventions.
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dure intra-aortic balloon pump, use of non-stent
device, use of thrombin inhibitors, time of day, week-
end procedure), and angiographic findings (left main
disease, proximal left anterior descending lesion,
Society of Cardiac Angiography and Intervention
lesionclassification
19).Inaddition,weadjustedforhos-
pitalcharacteristics,includingannualprimarypercuta-
neous coronary intervention volume, teaching status,
ownership, and rural location.
Toassesstherobustnessofourfindings,werepeated
analyses excluding patients who arrived in shock
because time to treatment might be less important for
patients who do not present in shock.
20 To further
reduce sample heterogeneity, we repeated analyses in
thecohortofpatientswhopresentedwithinsixhoursof
symptom onset.
Logistic regression models accounted for clustering
of patients by hospital with Huber-White robust esti-
mates of standard error. Statistical analyses were con-
ducted with SAS 9.1 (SAS Institute, Cary, NC) and
StataSE 9.0 (Stata Corporation, College Station, TX).
RESULTS
The median door-to-balloon time in the study cohort
was 83 minutes (interquartile range 62-109 minutes),
with 25359 patients (57.9%) treated within 90 minutes
of admission (table 1). A greater proportion of patients
who had longer door-to-balloon times were women,
non-white, and, on average, older than patients with
shorter door-to-balloon times. In general, patients with
longer door-to-balloon times had more comorbidities
than patientswith shorter door-to-balloon times, includ-
ing a higher prevalence of previous myocardial infarc-
tion, heart failure, diabetes, hypertension, peripheral
vascular disease, and previous revascularisation.
Patients with shorter door-to-balloon times had a lower
incidence of cardiogenic shock and stenoses of the left
main and left anterior descending arteries, and a greater
proportion had Society of Cardiac Angiography and
InterventionIVlesions.Agreaterproportionofpatients
with shorter door-to-balloon times were treated on a
weekdaybetween8am and4pm andaturbanhospitals
(tables 2-4).
Mortality in the study cohort was 4.6% (1999/43801)
overall. Patients who died in hospital had a 14 minute
longer median door-to-balloon time than patients who
survived(96v82minutes,P<0.001).Patientswithlonger
door-to-balloontimegroupshadhighercrudemortality
across the four door-to-balloon time groups
(<60 minutes=3.2% (323/9971), 60-89 minutes=3.7%
(568/15388), 90-119 minutes=4.6% (473/10208),
≥120 minutes=7.7% (635/8234), P<0.001 for trend).
Logistic regression analysis with a third degree frac-
tional polynomial (door-to-balloon time, door-to-bal-
loon time
2, and door-to-balloon time
3) best modelled
the unadjusted association of door-to-balloon time
with mortality, showing an increased risk of mortality
associated with any delay in door-to-balloon time
(fig 1). Estimated unadjusted mortality ranged from
2.8% for patients with door-to-balloon times of
30 minutes to 9.8% for patients with door-to-balloon
times of 240 minutes (table 5).
Longer door-to-balloon times continued to be asso-
ciated with increased mortality after multivariable
adjustment (fig 2). A third degree fractional poly-
nomial model continued to provide the best fit for the
Table 4 |Hospital characteristics and door-to-balloon time in patients undergoing primary percutaneous coronary
intervention for ST elevation myocardial infarction. Figures are percentages of patients unless stated otherwise
Characteristic Overall
Door-to-balloon time (minutes)
Overall P P for trend <60 60-89 90-119 ≥120
No of patients 43 801 9971 15 388 10 208 8234 ——
Median annual primary PCI
volume (IQR)
144 (89-215) 145 (91-238) 146 (91-215) 143 (87-214) 135 (82-210) <0.001 <0.001
Hospital data unavailable 3.3 3.6 3.4 3.1 3.0 0.06 0.006
Rural hospital 0.5 0.5 0.5 0.7 0.5 0.20 0.83
Teaching hospital 48.7 51.2 48.3 47.3 48.2 <0.001 <0.001
Ownership:
Public 8.2 7.9 8.3 8.0 8.4
<0.001 — Not for profit 82.2 82.2 82.6 82.3 81.4
For profit 6.3 6.3 5.6 6.5 7.3
PCI=percutaneous coronary intervention, IQR=interquartile range.
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Fig 1 | Unadjusted in hospital mortality as function of door-to-
balloon time (modelled as fractional polynomial) with 95%
confidence intervals
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tality, with any delay in door-to-balloon time continu-
ing to be associated with an increased mortality risk.
Estimated adjusted mortality ranged from 3.0% for
patients with door-to-balloon time of 30 minutes to
10.3% for patients with door-to-balloon times of
240 minutes (table 5).
Findings were similar when we repeated analyses
excluding the 4166 patients who presented in shock.
In the 39635 patients without shock, longer door-to-
balloon times continued to be associated with higher
crude mortality (<60 minutes=1.7% (156/9111),
60-89 minutes=1.8% (247/14024), 90-119 minutes
=2.2% (203/9226), ≥120 minutes=3.6% (262/7274),
P<0.001 for trend). A third degree fractional poly-
nomialmodelalsoprovidedthebestfitfortheadjusted
association of door-to-balloon times with mortality in
patients without shock, with any increase in door-to-
balloon time associated with increased mortality
(results not shown).
DISCUSSION
Anydelayindoor-to-balloontimeforpatientswithST
elevation myocardial infarction undergoing primary
percutaneous coronary intervention is associated with
higher mortality, even among patients treated within
90 minutes of admission. The mortality risk with
door-to-balloon time persists irrespective of the length
of the treatment delay. Our data suggest that physi-
cians could reduce mortality among such patients by
minimising door-to-balloon time to the greatest extent
possible, even among those treated within times
recommended by guidelines.
Comparison with other studies
Our analysis improves on previous studies that mod-
elled time to treatment as a categorical
457810-1420-24 or
continuous linear variable.
239Use of categorical vari-
ables might result in a loss of statistical power, which
could explain why certain studies report no increased
risk associated with delayed time to treatment.
20-24
Alternatively, by modelling time to treatment as a lin-
ear continuous variable, previous analyses assumed
each additional delay in treatment was associated
with the same additional increased risk in mortality,
which is not necessarily true.
25 Neither approach
accounts for the possibility that the mortality risk asso-
ciated with time to treatment might vary over time. By
usingfractionalpolynomialregression,weassessedthe
association of door-to-balloon time and mortality
using statistical modelling techniques that made no
assumptions regarding the shape of the association
between time to treatment and mortality.
Our principal finding of an immediate increase in
mortality associated with any delay in door-to-balloon
time reconciles competing reports concerning the
shape of the mortality risk associated with delayed pri-
mary percutaneous coronary intervention. While
some studiesfound that increasedmortality associated
with delays were present solely within the first few
hours of presentation and then plateaued,
714 others
had suggested the reverse—a risk that was initially
unchanged and increased only after a few hours of
delay.
1213 Our study suggests that both reports might
becorrectinthatthemortalityriskassociatedwithany
delay in time to treatment might be present immedi-
ately after admission and persist for several hours. A
closer assessment of previous studies indicates that
many, in fact, suggest such a consistent trend of
increased mortality with any delay in time to treat-
ment. For instance, although Cannon and colleagues
reported that mortality associated with longer door-
to-balloon time manifested after two or more hours of
delay,thereisacleartrendtowardsincreasedmortality
inpatientswithdoor-to-balloontimesof61-90minutes
and 91-120 minutes.
13 Furthermore, the few studies
that have also modelled time to treatment as a contin-
uous variable have similarly shown increases in
adverse outcomes associated with any delay in
M
o
r
t
a
l
i
t
y
 
(
%
)
0
6
9
12
15
3
15 45 75 105 135 165 195 225
Door to balloon time (minutes)
Fig 2 | Adjusted in hospital mortality as function of door-to-
balloon time (modelled as fractional polynomial) with 95%
confidence intervals
Table 5 |Estimated in hospital mortality (95% confidence interval) by door-to-balloon time in
patients undergoing primary percutaneous coronary intervention for ST elevation myocardial
infarction
Time (minutes) Unadjusted Adjusted*
15 2.6 (2.3 to 2.8) 2.9 (2.8 to 3.1)
30 2.8 (2.5 to 3.0) 3.0 (2.9 to 3.2)
45 3.1 (2.8 to 3.3) 3.2 (3.1 to 3.3)
60 3.4 (3.2 to 3.7) 3.5 (3.4 to 3.6)
75 3.9 (3.7 to 4.1) 3.8 (3.7 to 4.0)
90 4.4 (4.2 to 4.6) 4.3 (4.2 to 4.4)
105 5.0 (4.8 to 5.2) 4.9 (4.8 to 5.0)
120 5.6 (5.4 to 6.0) 5.6 (5.4 to 5.7)
135 6.3 (6.0 to 6.7) 6.3 (6.1 to 6.4)
150 7.0 (6.6 to 7.5) 7.0 (6.8 to 7.2)
165 7.7 (7.2 to 8.3) 7.7 (7.5 to 8.0)
180 8.4 (7.7 to 9.1) 8.4 (8.2 to 8.7)
195 8.9 (8.2 to 9.8) 9.1 (8.8 to 9.4)
210 9.4 (8.5 to 10.3) 9.7 (9.3 to 10.0)
225 9.7 (8.7 to 10.8) 10.1 (9.7 to 10.4)
240 9.8 (8.7 to 11.0) 10.3 (10.0 to 10.7)
*Adjusted for sex, age, race, findings on presentation, medical history, procedural characteristics, angiographic
findings, and hospital factors.
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23Assuch,differencesinstudyfindingscon-
cerningthespecificshapeoftheassociationofdoor-to-
balloon time and mortality largely reflect the manner
in which different studies have modelled time to treat-
ment rather than contradictory findings regarding the
relation between time and outcomes.
Pathophysiology of delayed time to treatment
An increased mortality risk associated with delayed
time to treatment in patients undergoing primary per-
cutaneouscoronaryinterventionisconsistentwithcur-
rent pathophysiological models of myocardial
infarction. Experimental models have shown that the
continuous, progressive “wave front of necrosis” lar-
gely depends on the duration of ischaemia.
26-29 Thus,
patients with longer door-to-balloon times will experi-
ence longer periods of vessel occlusion, resulting in
more ischaemia and greater necrosis than patients
with shorter times to treatment.
30 Although there
might be benefits to reperfusion therapy performed
after long delays, including improved ventricular
remodelling and reduced susceptibility to arrhythmic
events,
31ourdatasuggestthatthesebenefitsdonotoff-
set the underlying myocardial necrosis and attendant
processes resulting from longer delays in time to
treatment.
32Thishypothesisissupportedbytheobser-
vation that patients transferred for primary percuta-
neous coronary intervention achieve similar rates of
normal complete antegrade perfusion (TIMI 3 flow)
as patients who are not transferred but have larger
infarcts and poorer myocardial salvage.
33
Implications for practice
We believe our finding that any minute of delay in
treatment is associated with an increased risk of mor-
tality has important implications for clinical practice.
Notably,our datasuggestthatthereisno“floor”tothe
mortality reduction that can be achieved by reducing
time to treatment. As such, further reductions in door-
to-balloon times, even below the 90 minute bench-
mark endorsed by clinical practice guidelines, offer
the potential to significantly reduce mortality. For
instance, our data show that reducing average door-
to-balloon times from 90 minutes to 60 minutes
might reduce in hospital mortality by as much as
0.8% (from 4.3% to 3.5%). A further 30 minute reduc-
tion in door-to-balloon to an average of 30 minutes
offers the potential of an additional 0.5% reduction
(from 3.5% to 3.0%), underscoring the non-linear rela-
tion between time to treatment and mortality. Rather
than accepting a 90 minute door-to-balloon time
benchmark for primary percutaneous coronary inter-
vention, our data support calls for an “as soon as pos-
sible” standard for patients undergoing primary
percutaneous coronary intervention.
34 Such an
approach, using necessary safeguards against inap-
propriate treatment, offers the potential for notable
reductions in mortality.
Study limitations
Our study has several limitations that merit considera-
tion.Firstly,wewereunabletoassesstheassociationof
time from the onset of symptoms to arrival at hospital
andmortalityortheassociationoftotalischaemictime
andmortality.Weattemptedtolimitthiseffectbycon-
ducting a secondary analysis restricted to patients who
presented within six hours of symptom onset and
found our results were similar. Furthermore, robust
assessmentof timefromonset ofsymptomstohospital
admissionmightbeproblematicinthatthesetimesrely
on patients’ reports and thus cannot be independently
verified, whereas door-to-balloon times are probably
more accurately recorded. Secondly, we assessed the
outcome of in hospital mortality and cannot comment
on the association of door-to-balloon time and mortal-
ity at later end points. Previous studies, however, have
reported that the association of door-to-balloon time
and mortality is comparable whether assessed during
hospital admission, at 30 days, or at one year. Finally,
as our analysis was based on observational data our
findings might be attributable to biases introduced by
unmeasured factors. We attempted to mitigate this
effect through robust risk adjustment but cannot pre-
clude the possibility of residual confounding by other
non-measured patient or hospital factors associated
with door-to-balloon time or mortality.
Conclusion
Door-to-balloon time is associated with mortality in
patients undergoing primary percutaneous coronary
intervention for ST elevation myocardial infarction.
Contrary to previous studies, we found that this risk
was present on admission and was not attenuated
with the passage of time, indicating that any delay in
door-to-balloontimeinsuchpatientsisassociatedwith
an increased mortality. As such, our findings suggest a
benefit from reducing door-to-balloon time for all
patients undergoing primary percutaneous coronary
intervention, including those currently treated within
90 minutes of hospital admission.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Clinical guidelines recommend that hospitals providing
primarypercutaneouscoronaryinterventiontopatientswith
ST segment elevation myocardial infarction treat within
90minutesofcontactwiththemedicalsystemoradmission
to hospital
Thespecificshapeoftherelationbetweenmortalityriskand
timetotreatment,andtheincrementalbenefitofreductions
in door-to-balloon times beyond 90 minutes, is unclear
WHAT THIS STUDY ADDS
Any delay in door-to-balloon time for patients with ST
elevation myocardial infarction undergoing primary
percutaneous coronary intervention is associated with
higher mortality, even among patients treated within
90 minutes of admission
Reducing door-to-balloon time to the greatest extent
possible for all patient, including those currently treated
within 90 minutes of admission, might reduce mortality
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